Who is sponsoring NCT02260557?

NCT02260557 is sponsored by Actelion.

What condition does NCT02260557 study?

NCT02260557 studies Raynaud's Phenomenon Secondary to Systemic Sclerosis.

What drugs are being tested in NCT02260557?

Interventions: Selexipag, Placebo.

What is the status of NCT02260557?

NCT02260557 is currently COMPLETED.

Last reviewed 2025-01-31 · How we verify

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

NCT02260557 Phase 2 COMPLETED

The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis (SSc).

Details

Lead sponsor	Actelion
Phase	Phase 2
Status	COMPLETED
Enrolment	74
Start date	2014-10
Completion	2015-06

Conditions

Raynaud's Phenomenon Secondary to Systemic Sclerosis

Interventions

Selexipag
Placebo

Primary outcomes

Average number of Raynaud's phenomenon (RP) attacks per week during the maintenance treatment period — From Day 26 to Day 56 ( +/- 7 days)
The number of RP attacks is determined from daily entries in electronic Diaries (eDiary).